CD4 and neoplasm: Pre-clinical study on HNSCC mouse models have shown that SCH58261,a A2AR antagonist, significantly decreases the population of CD4+ FOXP3+ Tregs and promotes a CD8+ T cell-mediated antitumor response, which lead to a delay in tumor growth [94].